Kaitlyn Lapen1, Christopher Sabol1, Amy L Tin2, Kathleen Lynch3, Alyse Kassa4, Xiaolin Mabli1, John Ford1, Elaine Cha1, Michael B Bernstein1, Lior Z Braunstein1, Oren Cahlon1, Bobby M Daly5, Kiri Sandler6, Susan A McCloskey7, Andrew J Vickers2, Atif J Khan1, Erin F Gillespie8. 1. Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Departments of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Departments of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Departments of Health Informatics, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Departments of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Department of Radiation Medicine, Oregon Health and Science University, Portland, Oregon. 7. Department of Radiation Oncology, University of California, Los Angeles, California. 8. Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York; Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: efgillespie@ucsd.edu.
Abstract
PURPOSE: We aimed to develop and study the implementation of a remote system for toxicity assessment and management of acute side effects of breast radiation using electronic patient-reported outcomes (ePROs). METHODS AND MATERIALS: A response-adapted Patient-Reported Outcomes Common Terminology Criteria for Adverse Events-based assessment for breast radiation toxicity was administered weekly during and for 8 weeks after radiation from June 2019 to July 2020. The care team received alerts when "severe" symptoms were reported by patients, who were then contacted. Treatment, clinic, and sociodemographic characteristics were abstracted from patient records. A subsample of patients and care team members was qualitatively interviewed at follow-up. RESULTS: Overall, 5787 assessments were sent to 678 patients, of whom 489 (72%) completed 2607 assessments (45%). Moderate or greater toxicity was reported by 419 responders (86%; 95% CI, 82%-89%). Clinician alerts for severe toxicity were generated for 264 assessments among 139 unique patients, of which 83% occurred posttreatment. The proportion of surveys that prompted an alert was significantly higher after treatment (219 [13%]) than during treatment (45 [5%]) (P < .001). Survey completion rates in the posttreatment period were higher among patients undergoing partial breast irradiation than postmastectomy radiation (incidence rate ratio, 0.70; 95% CI, 0.60-0.81) (P < .001) despite these patients experiencing less severe toxicity. Interviews (15) found that patients had a positive experience with ePROs, although many thought the primary purpose was for research rather than symptom management. CONCLUSIONS: With the majority of toxicity occurring after breast radiation has ended, remote symptom monitoring with ePROs appears to fill a gap in clinical practice, particularly for patients undergoing shorter courses of radiation. It is important to properly onboard patients and explain that the purpose of ePROs is to aid clinical care. Further research is needed to determine whether the costs associated with ePROs can be offset by reducing routine clinic visits and whether this approach is acceptable and appropriate.
PURPOSE: We aimed to develop and study the implementation of a remote system for toxicity assessment and management of acute side effects of breast radiation using electronic patient-reported outcomes (ePROs). METHODS AND MATERIALS: A response-adapted Patient-Reported Outcomes Common Terminology Criteria for Adverse Events-based assessment for breast radiation toxicity was administered weekly during and for 8 weeks after radiation from June 2019 to July 2020. The care team received alerts when "severe" symptoms were reported by patients, who were then contacted. Treatment, clinic, and sociodemographic characteristics were abstracted from patient records. A subsample of patients and care team members was qualitatively interviewed at follow-up. RESULTS: Overall, 5787 assessments were sent to 678 patients, of whom 489 (72%) completed 2607 assessments (45%). Moderate or greater toxicity was reported by 419 responders (86%; 95% CI, 82%-89%). Clinician alerts for severe toxicity were generated for 264 assessments among 139 unique patients, of which 83% occurred posttreatment. The proportion of surveys that prompted an alert was significantly higher after treatment (219 [13%]) than during treatment (45 [5%]) (P < .001). Survey completion rates in the posttreatment period were higher among patients undergoing partial breast irradiation than postmastectomy radiation (incidence rate ratio, 0.70; 95% CI, 0.60-0.81) (P < .001) despite these patients experiencing less severe toxicity. Interviews (15) found that patients had a positive experience with ePROs, although many thought the primary purpose was for research rather than symptom management. CONCLUSIONS: With the majority of toxicity occurring after breast radiation has ended, remote symptom monitoring with ePROs appears to fill a gap in clinical practice, particularly for patients undergoing shorter courses of radiation. It is important to properly onboard patients and explain that the purpose of ePROs is to aid clinical care. Further research is needed to determine whether the costs associated with ePROs can be offset by reducing routine clinic visits and whether this approach is acceptable and appropriate.
Authors: Stephanie L Pugh; Joseph P Rodgers; Katherine A Yeager; Ronald C Chen; Benjamin Movsas; Roseann Bonanni; James Dignam; Deborah W Bruner Journal: Int J Radiat Oncol Biol Phys Date: 2020-06-24 Impact factor: 7.038
Authors: Anders Widmark; Adalsteinn Gunnlaugsson; Lars Beckman; Camilla Thellenberg-Karlsson; Morten Hoyer; Magnus Lagerlund; Jon Kindblom; Claes Ginman; Bengt Johansson; Kirsten Björnlinger; Mihajl Seke; Måns Agrup; Per Fransson; Björn Tavelin; David Norman; Björn Zackrisson; Harald Anderson; Elisabeth Kjellén; Lars Franzén; Per Nilsson Journal: Lancet Date: 2019-06-18 Impact factor: 79.321
Authors: S G Brearley; Z Stamataki; J Addington-Hall; C Foster; L Hodges; N Jarrett; A Richardson; I Scott; M Sharpe; D Stark; C Siller; L Ziegler; Z Amir Journal: Eur J Oncol Nurs Date: 2011-04-13 Impact factor: 2.398
Authors: Anamaria R Yeung; Stephanie L Pugh; Ann H Klopp; Karen M Gil; Lari Wenzel; Shannon N Westin; David K Gaffney; William Small; Spencer Thompson; Desiree E Doncals; Guilherme H C Cantuaria; Brian P Yaremko; Amy Chang; Vijayananda Kundapur; Dasarahally S Mohan; Michael L Haas; Yong Bae Kim; Catherine L Ferguson; Snehal Deshmukh; Deborah W Bruner; Lisa A Kachnic Journal: J Clin Oncol Date: 2020-02-19 Impact factor: 44.544
Authors: Simona F Shaitelman; Xiudong Lei; Alastair Thompson; Pamela Schlembach; Elizabeth S Bloom; Isidora Y Arzu; Daniel Buchholz; Gregory Chronowski; Tomas Dvorak; Emily Grade; Karen Hoffman; George Perkins; Valerie K Reed; Shalin J Shah; Michael C Stauder; Eric A Strom; Welela Tereffe; Wendy A Woodward; Diana N Amaya; Yu Shen; Gabriel N Hortobagyi; Kelly K Hunt; Thomas A Buchholz; Benjamin D Smith Journal: J Clin Oncol Date: 2018-10-31 Impact factor: 44.544
Authors: A Murray Brunt; Duncan Wheatley; John Yarnold; Navita Somaiah; Stephen Kelly; Adrian Harnett; Charlotte Coles; Andrew Goodman; Amit Bahl; Mark Churn; Rada Zotova; Mark Sydenham; Clare L Griffin; James P Morden; Judith M Bliss Journal: Radiother Oncol Date: 2016-04-01 Impact factor: 6.280
Authors: Reshma Jagsi; Kent A Griffith; Frank Vicini; Thomas Boike; Michael Dominello; Gregory Gustafson; James A Hayman; Jean M Moran; Jeffrey D Radawski; Eleanor Walker; Lori Pierce Journal: JAMA Oncol Date: 2022-06-01 Impact factor: 33.006
Authors: Matthew Chan; Robert Olson; Vincent Lapointe; Jeremy Hamm; Francois Bachand; Caroline Holloway; Christina Parsons; Peter Lim Journal: Curr Oncol Date: 2022-05-05 Impact factor: 3.109
Authors: Cheryl Duzenli; Elisa K Chan; Theodora Koulis; Sheri Grahame; Joel Singer; David Morris; Josslynn Spence; Terry Lee; Levi Burns; Robert A Olson Journal: Curr Oncol Date: 2022-07-07 Impact factor: 3.109